Department of Clinical Haematology, Manchester Royal Infirmary, Manchester, United Kingdom.
Hematology Am Soc Hematol Educ Program. 2009:97-105. doi: 10.1182/asheducation-2009.1.97.
The management of factor XI deficiency is not straightforward for three reasons: firstly, the role of this factor in the coagulation pathway is not clearly understood; secondly, the bleeding tendency, although mild, is unpredictable and does not clearly relate to the factor XI level; and thirdly, all treatment products, although available, have some potentially serious side effects. These factors (or enigmas) contribute to the variable management of patients with this coagulation factor deficiency, but recent research is helping to clarify some of these areas.
因子 XI 缺乏症的管理并不简单，原因有三：首先，该因子在凝血途径中的作用尚不清楚；其次，尽管出血倾向较轻，但不可预测，且与因子 XI 水平无明显关系；第三，所有治疗产品虽然都有，但都存在一些潜在的严重副作用。这些因素（或谜）导致了此类凝血因子缺乏症患者的治疗管理存在差异，但最近的研究正在帮助阐明其中的一些领域。
